Infertility
Conditions
Keywords
Anti-Mullerian Hormone, In-Vitro fertilization
Brief summary
The woman fertility decrease with the age and there is a closely link with the ovarian reserve, the number of available eggs in the ovaries. Therefore, it is important to evaluate the ovarian reserve with specific marker to have a better prediction of the response of the in vitro fertilization treatment and to have a better rate of pregnancy. Until now, a lot of clinical criteria (age, duration of the infertility, number of antral follicles) and biological (FSH, Oestradiol, Inhibin B, EFFORT test, number of the eggs at the retrieval day) was suggested to help for the estimation of the ovarian reserve. Since couple of years, the anti-müllerian hormone (AMH) is recognize to be one of the best ovarian reserve marker, it corresponding the number of antral follicles, it is more sensitive and predictive. Moreover, during the In-Vitro Fertilization, the anti-müllerian hormone can provide the weak responds at the stimulation and the reverse, the risk of excessive responds (hyperstimulation). To choose the gonadotropin doses to administrate (stimulation ovarian hormone) during an In-Vitro Fertilization protocol, we need to know the anti-müllerian hormone dosage. However, if the anti-müllerian hormone is recognize to evaluate the quantity of available eggs in the ovaries, his role to determine the quality of these eggs still discussed. The goal of this study is to verify if the serum anti-müllerian hormone (blood) is a good indicator for the quality of the reserve ovarian evaluating the impact of anti-müllerian hormone rate on the pregnancy rate and implantation rate, during stimulate In-Vitro Fertilization protocol.
Interventions
None listed
Sponsors
Clinique Ovo
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No
Inclusion criteria
* All infertile patients aged between 18 and 43 years * Patients with a prescription for a stimulated In-Vitro Fertilization cycle
Exclusion criteria
* Presence of endocrine disease: diabetes, hyperprolactinemia, abnormal thyroid-stimulating hormone (TSH) or Cushing syndrome * Renal or hepatic impairment known
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pregnancy rates | 7 weeks | Clinical pregnancy rates per cycle and per transfer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative pregnancy rates | 5 years | Cumulative pregnancy rates including all frozen embryo transfer |
| Number of eggs | 4 weeks | Number of eggs retrieve at the end of the stimulated in-vitro fertilization cycle |
| Number of embryos | 4 weeks | Number of embryos obtain at the end of the stimulated in-vitro fertilization cycle |
Countries
Canada
Outcome results
None listed